Morgan Stanley
INBX icon

Morgan Stanley’s Inhibrx INBX Stock Holding History

Morgan Stanley’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124M Buy
1,308,051
+44,973
+4% +$4.51M 0.01% 1390
2026
Q1 		$84.9M Buy
1,263,078
+95,350
+8% +$7.07M 0.01% 1582
2025
Q4 		$92.3M Buy
1,167,728
+724,872
+164% +$49.4M 0.01% 1524
2025
Q3 		$14.9M Buy
442,856
+415,048
+1,493% +$10.2M ﹤0.01% 3166
2025
Q2 		$397K Sell
27,808
-9,092
-25% -$118K ﹤0.01% 5566
2025
Q1 		$516K Sell
36,900
-2,815
-7% -$38.2K ﹤0.01% 5313
2024
Q4 		$612K Sell
39,715
-199,525
-83% -$3.04M ﹤0.01% 5339
2024
Q3 		$3.75M Buy
239,240
+3,324
+1% +$46.7K ﹤0.01% 4186
2024
Q2 		$3.34M Buy
+235,916
New +$3.69M ﹤0.01% 4208

Other funds holding INBX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Morgan Stanley's INBX Position: Q2 2026 in Review

Morgan Stanley increased its Inhibrx (INBX) stake by 3.6% in Q2 2026, buying an estimated $4.51M and bringing the position to 1,308,051 shares worth $124M. The position accounts for 0.01% of the portfolio, ranked #1390.

Morgan Stanley first reported a position in INBX in Q2 2024 and has held it in 9 quarters since. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Morgan Stanley held 1,308,051 shares of Inhibrx worth $124M as of Q2 2026.
  • Morgan Stanley bought 44,973 Inhibrx shares in Q2 2026, an estimated $4.51M.
  • Inhibrx made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1390 holding.
  • Morgan Stanley first reported a position in Inhibrx in Q2 2024 and has held it in 9 quarters since.
  • 163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.